Ac immune reports first quarter 2023 financial results and provides a corporate update

Ac immune reports first quarter 2023 financial results and provides a corporate update aci-24.060 anti-abeta vaccine showed positive initial safety and immunogenicity in first alzheimer's disease (ad) cohort in abate phase 1b/2 trial; further abate immunogenicity and safety data in higher dose ad cohorts expected in h2 2023 with amyloid-beta-pet imaging data in h1 2024 pi-2620 tau pet tracer pivotal phase 3 advance trial in ad initiated by partner life molecular imaging ad/pd™ 2023 conference featured ten presentations from ac immune strong chf 105.4 million cash position provides cash for operations into q3 2024 lausanne, switzerland, april 28 , 202 3 – ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the first quarter ended march 31, 2023, and provided a corporate update. dr. andrea pfeifer, ceo of ac immune sa, commented: “recent accomplishments reaffirm our industry-leading position in developing vaccines and diagnostics for neurodegenerative diseases supporting the transition to targeted treatment and disease prevention.
ACIU Ratings Summary
ACIU Quant Ranking